Transcatheter edge-to-edge repair is better than medical therapy alone in patients with heart failure and mitral regurgitation

London, United Kingdom – 31 August 2024: Mitral transcatheter edge-to-edge repair (M-TEER) reduced cardiovascular death and heart failure (HF)-related hospitalisations with improved health status in patients with HF and moderate to severe functional mitral regurgitation (FMR), according to late-breaking research presented in a Hot Line session today at ESC Congress 2024.1  

“Patients with FMR who are ineligible for surgery have limited treatment options. When M-TEER was studied previously, mainly in patients with severe FMR, one trial showed positive effects2 while the other was neutral.3 RESHAPE-HF2 now provides additional compelling evidence for using M-TEER over optimal medical therapy alone, which will help to guide medical decision making,” said Principal Investigator, Professor Stefan Anker from the Charite University Hospital, Berlin, Germany. 

This investigator-initiated randomised controlled trial recruited patients with symptoms of HF (New York Heart Association [NYHA] class ≥2) despite optimal guideline-directed medical therapy, who had left ventricular ejection fraction [LVEF] ≥20% and ≤50%, MR grade 3+ or 4+, and had a recent hospitalisation for HF or elevated plasma natriuretic peptide concentrations within the last 90 days. Patients for whom mitral valve surgery was recommended were not eligible. Patients were randomised 1:1 to M-TEER plus optimal medical therapy or optimal medical therapy alone. 

The three primary endpoints were: 1) composite rate of total (first and recurrent) HF hospitalisations and cardiovascular death within 24 months; 2) the rate of total HF hospitalisations within 24 months; and 3) the change from baseline to 12 months in the Kansas City Cardiomyopathy Questionnaire (KCCQ) overall score, which assesses the impact of HF on quality of life.  

In total, 505 patients were randomised from 30 centres in nine countries. The mean age was 70 years and 20% were female. The mean LVEF was 31% and HF was NYHA class III or IV in around three-quarters of patients. The mean KCCQ overall summary score was 46, which indicates significant symptoms and limitations due to HF. 

At 24 months, the rate of total hospitalisations for HF and cardiovascular death was significantly lower in the M-TEER group vs. the control group (37.0 per 100 patient-years vs. 58.9 per 100 patient-years; rate ratio 0.64; 95% confidence interval [CI] 0.48–0.85; p=0.002). The rate of total hospitalisations for HF within 24 months was significantly reduced by 41% in the M-TEER group vs. the control group (26.9 per 100 patient-years vs. 57.8 per 100 patient-years; rate ratio 0.59; 95% CI 0.42–0.82; p=0.002). In addition, the mean (standard deviation [SD]) change from baseline to 12 months in the KCCQ overall summary score was greater (improved) in the M-TEER group (+21.6 [26.9]) than in the control group (+8.0 [24.5]), resulting in a mean difference of +10.9 points (95% CI 6.8–15.0; p<0.001). 

During the total follow-up of 38.1 (18.1) months, there was no difference between the groups for all-cause mortality (17.0% in the M-TEER group vs. 18.5% in the control group; hazard ratio 0.90; 95% CI 0.71–1.13). Periprocedural adverse events were reported in 4 patients (1.6%) in the M-TEER group. 

Professor Anker concluded: “These findings provide reassurance about the benefits of M-TEER in patients with moderate to severe FMR and HF, which may help to strengthen and also broaden recommendations regarding its use in the future.” 

ENDS 

Notes to editor 

Funding:  The legal sponsor of the study was the University Medical Center Göttingen (Germany). Financial support for the trial was provided through an unrestricted grant from Abbott Laboratories to the University Medical Center Göttingen (Germany). 

Disclosures: Stephan Anker reports grants and personal fees from Vifor and Abbott Vascular, and personal fees for consultancies, trial committee work and/or lectures from Actimed, AstraZeneca, Bayer, Bioventrix, Boehringer Ingelheim, Brahms, Cardiac Dimensions, Cardior, Cordio, CVRx, Cytokinetics, Edwards, Farraday Pharmaceuticals, GSK, HeartKinetics, Impulse Dynamics, Medtronic, Novartis, Novo Nordisk, Occlutech, Pfizer, Regeneron, Relaxera, Repairon, Scirent, Sensible Medical, Servier, Vectorious and V-Wave. He reports that he is the named co-inventor of two patent applications regarding MR-proANP (DE 102007010834 & DE 102007022367), but he does not benefit personally from the related issued patents. 

References and notes 

1‘RESHAPE-HF2 - Percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure’ will be discussed during Hot Line 3 on Saturday 31 August  in room London. 

2Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med. 2018;379:2307–2318.  

3Obadia JF, Messika-Zeitoun D, Leurent G, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med. 2018;379:2297–2306. 

ESC Press Office 
Tel: +33 6 61 40 18 84  

Email: press@escardio.org 

The hashtag for ESC Congress 2024 is #ESCCongress 

Follow us on X @ESCardioNews  

Journalists are invited to become accredited and register here. 

Check out the ESC Media and Embargo Policy. 

About ESC Congress 2024 

It is the world’s largest gathering of cardiovascular professionals, disseminating ground-breaking science both onsite in London and online – from 30 August to 2 September. Explore the scientific programme. More information is available from the ESC Press Office at press@escardio.org. 

About the European Society of Cardiology  

The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.